Source: Drug Development Technology

Altavant Sciences: Altavant doses first patient in ELEVATE 1 trial of PAH drug

Altavant Sciences has dosed the first patient in the ELEVATE 1 trial of its lead candidate rodatristat ethyl to treat...Read More...The post Altavant doses first patient in ELEVATE 1 trial of PAH drug appeared first on Drug Development Technology.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Bill Symonds's photo - CEO of Altavant Sciences

CEO

Bill Symonds

CEO Approval Rating

90/100

Altavant Sciences is a biopharmaceutical company that develops and commercializes drug-based therapy for the treatment of respiratory diseases. Read more